The collaboration between 24 biopharmaceutical companies advances access to NCD prevention and care in low- and lower-middle income countries.

Bringing together over 35 partners, the campaign raises awareness about public health threats posed by falsified medicines and gives a voice to personally affected individuals.

IFPMA and WHO-AFRO cooperated to improve prevention, screening, and treatment of breast & cervical cancers through the AFRO Comprehensive Cervical Cancer Initiative.

IFPMA & the International Atomic Energy Agency (IAEA) joined forces to make a difference in comprehensive cancer control through their Programme of Action for Cancer Therapy (PACT). The two organisations also collaborate on training and education of the health workforce.

IFPMA provides expert guidance to support the creation of a new industry Code of Conduct in Kenya and the promotion of ethical practices.

For over 20 years, the innovative biopharmaceutical industry has supported the MDGs and today it supports SDG 3 and SDG 17 through multi-stakeholder collaboration at local, national and global levels.

IFPMA’s Africa Regulatory Network partners with African Medicines Regulatory Harmonization (AMRH), regulatory authorities and relevant stakeholders to encourage greater harmonization and convergence of regulatory requirements.